Ku Sae Kwang, Kim Hyemee, Kim Joo Wan, Kang Ki Sung, Lee Hae-Jeung
Department of Anatomy and histology, College of Korean Medicine, Daegu Haany University, Gyeongsan, South Korea.
Department of Nutrition and Food Science, Texas A&M University, College Station TX, United States of America.
J Ethnopharmacol. 2017 Feb 23;198:205-213. doi: 10.1016/j.jep.2017.01.010. Epub 2017 Jan 9.
Hemomine (HM) is an herbal mixture consisting of 5 varieties of the hematopoietic herbal extracts (Angelica gigas Nakai, Cnidium officinale Makino, Paeonia lactiflora Pall., Rehmannia glutinosa Liboschitz ex Stueudel, Glycyrrhiza uralensis Fischer).
Anemia has been treated with iron supplements, whereas it could cause adverse side effects such as digestive discomfort. In the present study, HM was applied to SHA rats to test for several activities so as to verify its therapeutic potentials on anemia and digestive discomfort.
Sprague-Dawley rats were assigned to seven groups: (Two controls, two references (ferric hydroxide polymatose (FM) and ferritin extract glycerin hydrate (FA)), three different concentrations of HM, n=8 per groups), and induced subacute hemorrhagic anemia (SHA) through blood exsanguinations once a day for 7 days.
The SHA animal model showed changes in the markers related to classic iron-deficient and regenerative anemia in this experiment. However, the SHA related anemic signs were dose-dependently inhibited by the administration of HM 2, 1, and 0.5ml/kg for 7 days, and more favorably than the equal dosages of FM and FA. In addition, FM and FA showed the typical constipation signs, including reduction of in thickness of the colonic mucosa, in contrast, HM 2, 1, and 0.5ml/kg groups had no effects on the gastrointestinal motilities and the colonic mucous components when compared to the controls. The results suggested that the HM significantly showed to have therapeutic effects in the experimental SHA in rats, and is more potent than the commercial iron supplement through the proliferation of hematopoietic stem cells with reduced digestive discomfort.
Therefore, Hemomine may prove to be a promising hematopoietic and therapeutic agent for anemia.
Hemomine(HM)是一种草药混合物,由5种造血草药提取物(当归、川芎、白芍、熟地黄、甘草)组成。
贫血一直通过补充铁剂进行治疗,但其可能会引起诸如消化不适等不良副作用。在本研究中,将HM应用于亚急性失血性贫血(SHA)大鼠,以测试其多种活性,从而验证其对贫血和消化不适的治疗潜力。
将Sprague-Dawley大鼠分为七组:(两个对照组、两个参考组(聚麦芽糖铁(FM)和水合甘油铁蛋白提取物(FA))、三个不同浓度的HM组,每组n = 8只),通过每天放血一次,持续7天诱导亚急性失血性贫血(SHA)。
在本实验中,SHA动物模型显示出与经典缺铁性和再生性贫血相关标志物的变化。然而,给予2、1和0.5ml/kg的HM持续7天可剂量依赖性地抑制与SHA相关的贫血症状,且效果优于同等剂量的FM和FA。此外,FM和FA显示出典型的便秘症状,包括结肠黏膜厚度减小,相比之下,与对照组相比,2、1和0.5ml/kg的HM组对胃肠动力和结肠黏液成分没有影响。结果表明,HM在大鼠实验性SHA中显著显示出治疗作用,并且通过促进造血干细胞增殖且减少消化不适,其比市售铁补充剂更有效。
因此,Hemomine可能被证明是一种有前途的治疗贫血的造血和治疗药物。